Concepedia

Michelle Clasquin

MC

Statistics

Publications

17

Citations

3.4K

H-Index

16

Active since

2010

Affiliations

Agios Pharmaceuticals (United States)(Current)

Pfizer (United States)

Princeton University

ID Genomics (United States)

Michelle Clasquin is an author at Agios Pharmaceuticals (United States) specializing in life sciences, biochemistry, and molecular oncology.

ORCID

Publications per year

2010–2025

17

Publications

17

Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

Krushna C. Patra, Qi Wang, Prashanth T. Bhaskar et al. · Cancer Cell · 2013 · 859 citations · Full text

, , +17

LC‐MS Data Processing with MAVEN: A Metabolomic Analysis and Visualization Engine

Michelle Clasquin, Eugene Melamud, Joshua D. Rabinowitz · Current Protocols in Bioinformatics · 2012 · 544 citations

, , +16

Metabolomic Analysis via Reversed-Phase Ion-Pairing Liquid Chromatography Coupled to a Stand Alone Orbitrap Mass Spectrometer

Wenyun Lu, Michelle Clasquin, Eugene Melamud et al. · Analytical Chemistry · 2010 · 514 citations

, , +16

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

Katya Marjon, Michael J. Cameron, Phong Quang et al. · Cell Reports · 2016 · 447 citations · Full text

, , +17

MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage

Peter Kalev, Marc L. Hyer, Zenon Konteatis et al. · Cancer Cell · 2021 · 234 citations

, , +7

1–5 of 17